We are developing cutting-edge immunotherapies based on Toll-like receptor (TLR) biology and its ability to modulate the immune system. Learn More >
Through our expertise in TLR biology we have designed compounds that stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >
HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary TLR9 agonist to enhance the immune response. HEPLISAV-B demonstrated positive results in Phase 3 trials. Subject to approval by the U.S. Food and Drug Administration, we plan to launch HEPLISAV-B in late 2016.